Nurix Therapeutics to Present at Upcoming Investor Conferences

Nurix Therapeutics will present at several investor conferences in September 2025, including the Wells Fargo Healthcare Conference, H.C. Wainwright Annual Global Investment Conference, RW Baird Healthcare Conference, Morgan Stanley Healthcare Conference, and Stifel Virtual Immunology & Inflammation Forum. The leadership team will present, and live webcasts will be available on the company's website for 30 days. The presentations will focus on the company's targeted protein degradation medicines for cancer and inflammatory diseases.

San Francisco, CA — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines, has announced its participation in several investor conferences in September 2025. The company's leadership team, including CEO Arthur T. Sands, M.D., Ph.D., CFO Hans van Houte, CCO John Northcott, and CBO Jason Kantor, will present at the following events:

1. Wells Fargo Healthcare Conference, Boston, MA — Fireside chat on September 3, 2025, at 1:30 p.m. ET
2. H.C. Wainwright Annual Global Investment Conference, New York, NY — Corporate presentation on September 8, 2025, at 1:30 p.m. ET
3. RW Baird Healthcare Conference, New York, NY — Fireside chat on September 9, 2025, at 10:50 a.m. ET
4. Morgan Stanley Healthcare Conference, New York, NY — Fireside chat on September 10, 2025, at 7:00 a.m. ET
5. Stifel Virtual Immunology & Inflammation Forum — Corporate presentation on September 16, 2025, at 11:00 a.m. ET

All presentations will be webcast live and archived for 30 days on the company's website. The webcasts will provide investors with the opportunity to hear from the leadership team about the company's pipeline of targeted protein degradation medicines, which focus on cancer and inflammatory diseases.

About Nurix Therapeutics

Founded in San Francisco, California, Nurix Therapeutics is a clinical-stage biopharmaceutical company specializing in targeted protein degradation medicines. The company's wholly owned, clinical stage pipeline includes degraders of Bruton’s tyrosine kinase (BTK) and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B). Additionally, Nurix is advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. The company's partnered drug discovery pipeline consists of a preclinical stage degrader of STAT6 and a clinical stage degrader of IRAK4 in collaboration with Gilead, among others.

Contact Information

For more information, please visit the company's website at [http://www.nurixtx.com](http://www.nurixtx.com) or contact the following:

- Investors: Kris Fortner, ir@nurixtx.com
- Media: Aljanae Reynolds, areynolds@wheelhouselsa.com

References

[1] [https://www.biospace.com/press-releases/nurix-therapeutics-to-participate-in-upcoming-septemberinvestor-conferences](https://www.biospace.com/press-releases/nurix-therapeutics-to-participate-in-upcoming-septemberinvestor-conferences)
[2] [https://www.stocktitan.net/news/NRIX/](https://www.stocktitan.net/news/NRIX/)